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ABSTRACT 
EFFECT OF JACKFRUIT-DERIVED EXTRACT CONSUMPTION ON 
COLITIS-ASSOCIATED COLON TUMORIGENESIS IN MICE 
SEPTEMBER 2020 
 
JINGWEN LIN, B.S., JIANGNAN UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST  
Directed by: Professor Guodong Zhang 
Colorectal cancer is the third most common cancer and the fourth most common 
cause of cancer-related death in the world. The global burden of colorectal cancer is also 
expected to increase by 60%, to over 2.2 million new cases and 1.1 million annual deaths, 
by the year 2030. Jackfruit is known for its packed nutrition including many antioxidants: 
vitamin C, carotenoids and flavanones. It has also been used in traditional medicine due 
to its potential protection against many chronic diseases. However, there is limited 
research studying the potential effect of jackfruit on colorectal cancer. Here, we used a 
well-established AOM/DSS mice model to investigate the impact of jackfruit-derived 
extracts on colitis-associated colorectal cancer. After 6-week treatment with diet 
containing 480 ppm jackfruit-derived extracts, the mice showed significantly alleviated 
colon tumorigenesis with a 46% decrease in tumor numbers of each mouse compared to 
vehicle group (2.1 ± 0.31 for 480 ppm jackfruit-derived fraction group vs 3.9 ± 0.67 for 
vehicle group, P  < 0.05). The expression of the pro-inflammatory cytokines (Il-6 and Inf-
γ) and pro-tumorigenic genes (Axin2, Vegf, Myc and Pcna) was also decreased in the 
group consuming 480 ppm jackfruit-derived extracts compared to the vehicle group. 
Together the results suggest that the consumption of jackfruit-derived extracts could 
protect against colitis-associated colorectal carcinogenesis in mice. 
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1.1 Introduction of Human Colorectal Cancer 
1.1.1 Incidence 
Colorectal cancer is the third most commonly diagnosed form of cancer globally, 
comprising 10.2% of all cancer diagnoses in 2018, according to WHO [1], [2].  
Colorectal cancer is also the third most common cancer in the United States, according to 
American Cancer Society. It is estimated that there will be 147,950 new cases of 
colorectal cancer in the U.S in 2020. Overall, the lifetime risk of developing colorectal 
cancer in the U.S. is about 1 in 23 (4.4%) for men and 1 in 25 (4.1%) for women [3]. The 
incidence rate escalates rapidly with age in the U.S., approximately doubling with each 5‐
year age increase until age 50 years and increasing by approximately 30% with 
subsequent groups aged 55 years and older [4]. 
1.1.2 Mortality 
Colorectal cancer is the second most deadly cancer worldwide, with about 881,000 
deaths estimated for 2018. The cumulative risk, at age 0 to 74 years, of dying from 
colorectal cancer is 1.12% among men and 0.70% among women globally [1]. In the 
United States, colorectal cancer is the third leading cause of cancer-related deaths in men 
and in women, and the second most common cause of cancer deaths when men and 
women are combined. The percent of colorectal cancer deaths is highest among people 
aged 75–84, with a median age at death 74 [5]. It's expected to cause about 53,200 deaths 
in the U.S. during 2020 [3]. 
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1.1.3 Trend 
The global burden of colorectal cancer is expected to increase by 60%, to over 2.2 
million new cases and 1.1 million annual deaths, by the year 2030 [6]. In the United 
States, the incidence rates of colorectal cancer for ages 20–49 years was 9.3 per 100,000 
in 1975 and is up to 13.7 per 100,000 in 2015, a percentage increase of 47.31%, although 
incidence rates in age groups 50 years and above has steadily decreased until 2011 [7]. 
Among individuals aged 50 to 64 years, however, declines in incidence of 2% to 3% per 
year during the 2000s have reversed in recent years, with rates during 2011 through 2016 
increasing by 1.0% per year [8]. Over the past 10 data years (2008‐2017) in the United 
States, mortality rate increased by 1.3% per year in individuals younger than 50 years, 
though death rates declined by 3% per year in individuals aged 65 years and older and by 
0.6% per year in individuals aged 50 to 64 years [9]. 
1.2 Animal Models of Colorectal Cancer 
With the large incidence and mortality of colorectal cancer, furthering scientific 
understanding of the disease to promote more effective preventions, diagnoses, and 
treatments presents an important and challenging problem. Controlled in vivo animal 
studies are one of the primary ways for the scientific community to conduct ethical 
studies in which the tumorigenesis process can be carefully studied in a biological setting 
approximating the human colon. There are a few aspects involved in selecting a good 
animal model for colorectal cancer study. First, the cancer that develops in the animal 
model should be limited to the large intestine or rectum so that researchers can study the 
development of the disease without the confounding effects of disease in other tissues. 
Second, the histologic and molecular features of colorectal lesions should be similar to 
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those observed in human tissue. Finally, the models should capture the complex cellular 
interactions that are relevant to human colon cancer. For example, though xenografts of 
human tumor into nude mice are often cited as highly relevant to the study of human 
cancer, these mice are immune-compromised and this eliminates the impact of immune 
system on the tumors [10]. Due to the similarities of genetic and physiological traits mice 
possess to those of humans, and relatively low maintenance requirements compared to 
larger mammals (e.g. pigs or dogs), mice are better models for studying the immune, 
endocrine, nervous, and other physiological systems. Like humans, mice have the ability 
to develop several diseases, such as cancer [11]. For research purposes, two major animal 
models of colorectal carcinogenesis are chemical or environmental agents induced 
colorectal tumors in rodents, which represent sporadic colorectal cancer, and genetically 
modified mice, which represent the hereditary familial adenomatous polyposis and 
hereditary non-polyposis colorectal cancer syndromes (HNPCC)  [12]. 
1.2.1 Colorectal cancer induced by exogenous agents 
A large number of chemicals are known to have mutagenic potential, and chemically 
induced tumors on rodents are generally used to study the wide range of epigenetic 
alterations found in sporadic or colitis-associated colorectal cancer [13]. Administration 
of the chemical compounds is possible via ad libitum feeding, oral gavage, intraperitoneal 
or intramuscular injection, or enema [14]. 
1.2.1.1 1,2-dimethylhydrazine (DMH) and azoxymethane (AOM) 
DMH and its metabolite AOM are the two most commonly used carcinogens to 
induce and promote colorectal cancer in rats and mice [15]. DMH is metabolically 
activated in the liver by a series of reactions through intermediates AOM and 
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methylazoxymethanol (MAM) which are metabolized predominantly by CYP2E1 in the 
liver and other enzymes in extrahepatic organs to the ultimate carcinogenic metabolite — 
highly reactive methyldiazonium ion — causing alkylation of DNA bases [16], [17]. 
DMH and AOM are alkylating agents that are typically injected intraperitoneally or 
subcutaneously over several weeks to induce development of tumors in the distal colon. 
The majority of these tumors harbor mutations in the β-catenin gene (Ctnnb1, 
the Ctnnb1 gene encodes β-catenin), which is similarly observed in hereditary 
nonpolyposis colorectal cancer in humans [18].These mutations affect the N-terminal 
amino acids of the β-catenin gene product, making the protein resistant to regulatory 
degradation, stabilizing β-catenin, and increasing WNT signaling to drive tumorigenesis 
[19]. In contrast to the majority of genetic mouse models producing tumors mainly in the 
small intestine, DMH/AOM-treated mice generate tumors predominantly in the distal 
colon, which enable researchers to study pathological process of colorectal cancer 
without the confounding factors of diseases in other tissues. In addition, tumor incidence 
and multiplicity can be altered by both genetic background and by diet [15]. This makes 
the models advantageous for the study of gene-gene and gene-environment interactions 
that influence the pathogenesis of colorectal cancer. However, some have questioned the 
translational potential of data generated with DMH/AOM model, since there is little 
evidence that a large proportion of human sporadic colorectal cancer results from 
exposure to alkylating agents [10]. As mentioned before, the activation of DMH/AOM 
carcinogenesis relies on the participation of various enzymes in the liver, therefore 
chemopreventative agents with potential interference with the metabolic pathway of 
DMH/AOM may modify colon carcinogenesis and affect study results [16], [17]. To 
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avoid interference between the compound and DMH/AOM activation, chemopreventive 
treatment can begin after carcinogen administration, that is, during the promotion or 
progression phase [20]. 
1.2.1.2 AOM / Dextran sulfate sodium (DSS) 
DSS-induced colitis animal model is widely used because of its simplicity and many 
similarities with human ulcerative colitis. The mechanism by which DSS induces 
intestinal inflammation in unclear but it is likely the result of damage to intestinal 
epithelial monolayer lining, leading to the entry of luminal bacteria and associated 
antigens into the mucosa and allowing the dissemination of proinflammatory intestinal 
contents into underlying tissues [21]. To create a model of colorectal tumors associated 
with chronic inflammation, a protocol combining AOM with an inflammatory agent, 
dextran sulfate sodium (DSS) salt, was introduced by Suzuki et al in 2007 [22]. Chronic 
inflammation leads to the formation of a microenvironment enriched with immune cells 
that produce pro-inflammatory cytokines and growth factors and, simultaneously, 
increase the local levels of reactive oxygen species. Subsequently, cell proliferation and 
the risk of DNA damage are increased. In the case of a long-lasting inflammatory 
response, cell transformation and tumorigenesis occur with high frequency. One of the 
evident advantages of the AOM and DSS combination is further reduction in the time 
needed for tumor formation. A single dose of AOM followed by five days of DSS 
treatment resulted in development of multiple colon tumors within 10 weeks compared to 
24-50 weeks of latency when only DMH/AOM is used [23], [24]. More importantly, 
studies in mice and rats have revealed that AOM/DSS-induced tumors display very 
similar features to human CRC even at the molecular level. Inactivating APC mutations 
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or activating β-catenin mutations, which mimics WNT stimulation and leads to β-catenin 
accumulation, is observed in the majority of colon cancers in both humans and rodents 
[25], [26]. Also consistent with findings in human colorectal cancer, AOM/DSS-induced 
tumors also have mutations of K-Ras and increased levels of enzymes involved in 
prostaglandin and nitric oxide synthesis, such as cyclooxygenase-2 (COX-2) and 
inducible nitric oxide synthase (iNOS) [27], [28]. However, a recent study that performed 
exome sequencing on colorectal cancer mice under AOM/DSS treatment and humans 
with colorectal cancer found that the top 20 most frequent mutation sites including APC, 
TP53, KRAS, NRAS, BRAF, PIK3CA, SMAD4 and FBXW7 in human CRC samples 
were not detected in AOM/DSS mice, questioning the compatibility of using AOM/DSS 
mouse model to mimic human colorectal cancer [29]. Nonetheless, because of its high 
reproducibility and potency, as well as the simple and affordable mode of application, the 
AOM/DSS model has become an outstanding model for studying colon carcinogenesis 
and a powerful platform for chemopreventive intervention studies [30].  
1.2.1.3 2-amino-1-methyl-6-phenylimidozo [4,5-b] pyridine (PhIP) 
PhIP is the most abundant heterocyclic aromatic amines (HAA) formed from the 
reaction between free amino acids, sugars and creatine at high temperatures during the 
cooking process of meat and fish, which most people are exposed to in daily life [31]. 
PhIP is metabolized by the liver enzyme CYP1A2 to N2-Hydroxy-PhIP, which then, after 
sulfation or acetylation, forms activated esters capable of DNA adduct formation [32], 
and then induces formation of colonic aberrant crypt foci, but fails to induce formation of 
colon tumors in mice [33], [34]. However, combining PhIP with either DSS treatment or 
treating ApcMin mice with PhIP can enhance tumorigenesis [35], [36]. Data obtained from 
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the study of PhIP in rodents is considered to be highly relevant to human cancer, since 
epidemiologic evidence links PhIP from cooked meat to increased colorectal cancer risk 
[37], [38]. In addition, stimulation of colon tumorigenesis by PhIP also occurs in mice 
consuming a high-fat diet, however the tumor incidence was relatively low [39], [40], 
[41]. PhIP was also found to lead to formation of mammary and prostate neoplasia 
besides causing colon tumorigenesis [42], which can lead to confounding effects in 
research. 
1.2.1.4 N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitrosourea 
(abbreviated as both MNU and NMU) 
MNNG and MNU are direct-acting carcinogens which have been administered to 
mice and rats to induce neoplasia in a variety of organs [43]. They are carcinogens which 
methylate nucleic acids and proteins, and covalently modify proteins [44]. However, 
some studies have found that MNU has failed to induce tumorigenesis selectively in 
colorectal tissue when administered orally, injected intraperitoneally or intramuscularly, 
and intrarectally, indicating that MNU might be a less competent carcinogenesis agent 
when studying the pathological progress of just colorectal cancer [45], [46], [47], [48]. 
On the other hand, it has been discovered that when MNNG was given intrarectally at a 
dose rate of 1–3 mg/rat/week for 20 weeks, it induced colon tumors in 100% of 
male F344 rats, and the neoplasms were all located in the distal colon and rectum [49]. 
However, the major weakness of MNNG is that the technique of intrarectal injection 
requires highly skilled technicians and quantification of carcinogens instilled intrarectally 
is difficult [50]. 
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1.2.2 Genetically modified mice models 
The development of gene targeting has enabled researchers to have a more controlled 
approach when studying colorectal cancer. The availability of genetic and genomic 
information, the ease of genetic manipulation through mutagenesis techniques and the 
ability to monitor the effects on a whole organism have made genetically engineered 
mice a very advantageous model of CRC. These advantages make mouse models 
fundamental when testing therapeutics, enabling efficacy and toxicity of the treatments to 
be analyzed but have their own limitations which will also be discussed here. 
1.2.2.1 Mice models for FAP 
FAP is an autosomal-dominant colorectal cancer syndrome, caused by a germline 
mutation in the adenomatous polyposis coli (APC) gene, on chromosome 5q21. It is 
characterized by hundreds of adenomatous colorectal polyps, with an almost inevitable 
progression to colorectal cancer with a high risk of metastasis at an average age of 35 to 
40 years [51]. One of the most widely used animal model for FAP is a type of mice 
termed Min or Apcmin/+ (multiple intestinal neoplasms). This mouse model was obtained 
by random mutagenesis using N-ethyl-N-nitrosourea. The Min mutation was found to 
have an autosomal dominant mutation at condon 850 in APC causing a truncated protein 
of 850 amino acids [52]. Apcmin/+  heterozygotes are born normally and have a reduced 
average lifespan of 150 days. These mice can develop more than 100 adenomas in the 
small intestine, and a small number of polyps in the colon depending on the genetic 
background [53]. Apcmin/+ mouse model has phenotypic and genetic similarities to FAP 
patients, making it an ideal model to investigate colon cancer. However, this model does 
not completely match the phenotype of FAP, an example being that FAP patients develop 
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adenomas predominately in the colon, whereas adenomas in Apcmin/+ mice are 
predominantly localized to the small intestine. One of the solutions is to treat 
Apcmin/+ female mice with 2% DSS, as Tanaka et al. and Cooper et al. have reported the 
increase in the incidence of colonic neoplasms and dysplastic crypts in female 
Apcmin/+ mice administered with DSS [54], [55]. Another solution is to cross Apc+/loxP 
mice with mice carrying CDX2P 9.5-NLS Cre transgene. Hinoi et al. reported that 
CDX2P-NLS Cre;Apc+/loxP (CPC;Apc) mice were found to develop 5 to 8 tumors in the 
colon and rectum, and only 3 tumors in distal small intestine on average [56]. Another 
limitation of the Apcmin/+ mouse model is that the adenomas are generally benign and do 
not progress to invasive colon cancer, probably due to the short lifespan of the mice. 
FAP patients have been found to exhibit a wide variety of APC mutations, which can 
affect both the phenotype and the prognosis [57]. To understand the precise roles of 
different APC mutations on the development of colorectal cancer, further studies were 
conducted using mice that carry different APC mutations which have been implicated in 
either the initiation or progression of colorectal cancer. These mouse models containing 
different mutations in the APC gene differ phenotypically by the number of polyps in the 
small intestine, colon, and levels of invasion. For example, a heterozygous mouse model 
for a truncation mutation at codon 716 in APC (ApcΔ716/+) contain 10 times the number of 
polyps in the small intestine compared to the Apcmin/+ mouse model [58], whereas the 
insertion of a neomycin cassette into exon 15 (Apc1638N) results in fewer polyps but with a 
marked increase in invasion [59]. Research in heterozygous APC mutations has not only 
increased the range of animal research models available for study of the disease, it also 
led to insights into the relationships between APC mutation type and human patient 
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prognosis. An example of this is the mouse model heterozygous for a truncation mutation 
in the APC gene at codon 1309 (Apc1309/+). This mouse model has a more severe 
phenotype than the Apcmin/+ mouse model, including a shorter lifespan and an increase in 
polyps in the colon, and FAP patients with this mutation also have an earlier onset of the 
disease and severe polyposis, making their phenotype more severe than patients with 
other APC mutations [60]. 
1.2.2.2 Mice models for HNPCC 
HNPCC is the most frequent form of hereditary colorectal cancer, and accounts for up 
to 5% of all colorectal cancers in the United States. HNPCC is inherited in an autosomal 
dominant fashion with high penetrance. Colorectal cancer patients diagnosed with 
HNPCC suffer an early onset of tumorigenesis, with a small subset of patients also 
developing tumors in the stomach and small intestine [53]. HNPCC is caused by 
mutations in the mismatch repair genes including MLH1, MSH2 and MSH6, which 
causes microsatellite instability, characterized by increased rates of replication errors 
[61]. In order to better understand this disorder, a mouse model that closely mirrors the 
genetic scenario in humans via heterozygous deletion of these genes was developed. 
However, this mouse model was unable to develop early-onset tumors, probably due to 
the short lifespan of mice [62]. On the other hand, homozygous knockout mice are cancer 
prone and develop tumors in multiple organs, and although they do 
develop gastrointestinal tumors, the cause of death is aggressive lymphoma [63], which 
does not yield an accurate model for HNPCC. By combining homozygous mutations for 
the mismatch repair genes with various germ-line APC mutations, much more accurate 
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models of HNPCC have been developed which display a phenotype of multiple early-
onset intestinal tumors [64], [65], [66]. 
1.3 Dietary factors in colorectal cancer 
1.3.1 Dietary factors in human colorectal cancer 
A higher incidence of colorectal cancer is observed in North America and Europe, 
whereas Africa and Asia have a lower incidence. In addition to the impact of race on the 
risk of colorectal cancer, a variety of epidemiological studies provide compelling 
evidence that diet and nutrition are important factors in the development of colorectal 
cancer in humans. During the past three decades, many large epidemiologic studies led 
by many prominent research institutes have discovered interesting associations between 
different diet choices and the risk of colorectal cancer. 
Some of the most prominent epidemiological studies on diet and colorectal cancer are 
the NIH-AARP DHS study (291,988 men and 197,623 women aged 50-71 years at 
baseline in 1995-1996 during 5 years of follow-up) [67], the EPIC study (>500,000 
participants from 10 European countries) [68], and the Scandinavian HELGA study 
(108,000 Danish, Swedish, and Norwegian people) [69]. Multiple studies including the 
DHS study discovered a positive association of red/processed meat with the risk of 
colorectal cancer [70], [71], [72]. Accordingly, the World Cancer Research Fund and the 
American Institute for Cancer Research listed red/processed meat as convincing factors 
for increasing the risk of colorectal cancer [73], [74]. High fiber intake from whole grains 
and cereals was found to be associated with a lower risk of colorectal cancer, supported 
by the EPIC study (cereals: Relative Risk: 0.87, 95% CI: 0.77–0.99, p-trend =0.003) [68], 
the DHS study (grain: Relative Risk: 0.51, 95% CI: 0.29–0.89, p-trend =0.01) [67], and 
 12 
the Scandinavian HELGA study (whole-grain wheat: Incidence Rate Ratio: 0.65, 95% 
CI: 0.50–0.84) [69]. Fruit and vegetable intake is also associated with the risk of 
colorectal cancer: the EPIC study observed a lower risk of colorectal cancer with higher 
consumption of fruits and vegetables combined among never and former smokers 
(Hazards Ratio: 0.86, 95% CI: 0.75–1.00, p-trend =0.04), while interestingly the 
consumption of fruits and vegetable was positively associated with colorectal cancer in 
current smokers [68]. A pooled meta-analysis by Wu et al. in 2012 that focused only on 
cruciferous vegetables and included 24 case–control and 11 prospective studies found a 
significant inverse relationship (Relative Risk: 0.82, 95% Cl: 0.75–0.90) between 
cruciferous vegetable intake and the risk of colorectal cancer [75].  
In addition to showing correlations between colorectal cancer risk and consumption 
of specific foods, epidemiological studies have also shown insightful results about the 
potential effects of overall, population-level diet styles on colorectal cancer. Researchers 
have observed that descendants of Japanese immigrants living in Hawaii were less likely 
to eat “Japanese-style” meals and more likely to eat “western-style” meals than first 
generation Japanese immigrants. In addition, US-born Japanese, regardless of sex, were 
taller, weighed more, and reported consuming higher quantities of meat, coffee, and total 
fat, but ate less tofu, green tea, and carbohydrates than Japanese living in Japan [76]. A 
classic 1999 study by Flood et al. found that US-born Japanese men experienced 
incidence rates of colorectal cancer twice as high as foreign-born Japanese men and about 
60% higher than those of US-born white men [77]. Assuming Japanese Americans have a 
relatively similar genetic profile compared to Japanese living in Japan, these results, in 
 13 
combination with the dietary patterns of US-born Japanese noted above, suggest that the 
lifestyle of a “western-style” diet may substantially increase the risk of colorectal cancer. 
1.3.2 Dietary factors in animal colorectal cancer models 
Besides the support of epidemiological studies on the strong connections between 
food/diet and the development of human colorectal cancer, many animal (especially 
mouse/rat) colorectal cancer studies have also shown the impact of food/diet on the risk 
of developing colorectal cancer. Fisher 344 rats administered with the carcinogen DMH 
were utilized to test the effect of red meat and calcium on colorectal cancer development. 
In comparison of the control rats, increased aberrant crypt foci (ACF) and mucin-
depleted foci (MDF) were observed in rats whose diet contains 60% red meat, while the 
effect was inhibited by the addition of calcium [78]. Fernández et al. discovered that a 
prebiotic-inulin reduced colon polyps caused by the over consumption of traditional 
red/processed meat by 49% in Fisher 344 rats administered with AOM/DSS [79]. 
Donohoe et al. found the combination of high-fiber diet and a probiotic-Butyrivibrio 
fibrosolvens protected BALB/c mice from AOM/DSS induced colorectal cancer [80]. 
Sulforaphane, a component of cruciferous vegetables, appears to be an effective anti-
cancer agent in cell culture, carcinogen-induced, and genetic cancer models. When 
sulforaphane is added at 300 or 600 μg/g to an AIN-76A diet for ApcMin mice, it reduced 
the average number of polyps significantly (25.3% and 47% respectively in the small 
intestine), and no polyps were observed in the large intestine [81]. In sum, multiple 
animal models have been utilized in aiding the characterization of food and diet on the 




EFFECT OF THE CONSUMPTION OF JACKFRUIT-DERIVED FRACTION ON 
COLON TUMORIGENESIS IN MICE 
 
2.1 Introduction 
Artocarpus heterophyllus, which is commonly known as jackfruit or jackfruit tree is a 
tropical climacteric fruit, belonging to the fig, mulberry, and breadfruit family 
(Moraceae) [82], is native to Western Ghats of India and common in Asia, Africa, and 
some regions in South America [83]. It is known to be the largest edible fruit in the world 
[84]. Jackfruit is rich in nutrients including carbohydrates, proteins, vitamins, minerals, 
and phytochemicals including lignans, isoflavones and saponins that led to its extensive 
use in traditional medicine due to its anticarcinogenic, antimicrobial, antifungal, anti-
inflammatory, wound healing, and hypoglycemic effects [85]. In addition, Ruiz-
Montanez et al. observed that jackfruit possesses compounds with chemoprotective 
properties to reduce the mutagenicity of aflatoxin B1 (AFB1) and proliferation of cancer 
cells [86]. Chen et al. also discovered that artocarpin, a compound extracted from 
jackfruit tree, exhibited potent cytotoxicity against human colon cancer cells including 
DLD1, HCT15, HCT116, HT29, and SW480 cells with IC50 values at around 15 μmol/L. 
The attenuation of colorectal tumorigenesis was also shown in AOM/DSS mice 
administered with 100 mg/kg artocarpin by oral gavage, with a significant increase of 
mice survival rate and reduced multiplicity of colon neoplasms by 56% (P < 0.001) [87]. 
Meanwhile, water-soluble polysaccharides extracted from jackfruit tree failed to show 
strong toxicity to human colon tumor cells, despite its exhibited immunomodulatory 
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activity as well as significant anti-oxidative effects [88]. In order to investigate the true 
effect of jackfruit-derived extracts on colorectal tumorigenesis in vivo, we conducted 
animal experiments with AOM/DSS-induced colorectal cancer model. 
2.2 Materials and methods  
2.2.1 Animal experiment 
C57BL/6 male mice at age 7 weeks, purchased from Charles River (Wilmington, 
MA), were maintained at the University of Massachusetts Amherst in a standard Specific 
Pathogen Free animal facility. The mice were divided into three groups: vehicle group 
had 11 mice, low dose jackfruit-derived fraction group (240 ppm) had 10 mice, high dose 
jackfruit-derived fraction group (480 ppm) had 10 mice. While mice of all groups were 
maintained on the same chow diet, all mice were injected with AOM (1mg/ml dissolved 
in PBS, 10mg/kg body weight); and one week later, the mice were given drinking water 
containing 2% DSS for one week. New diets were given to all groups of mice after one 
week of DSS treatment. Specifically, diets for all three groups consisted of 10 wt/wt % 
commercial corn oil and 0.5 mL/g % PEG 400 while the diet for low dose and high dose 
jackfruit-derived fraction groups also consisted of 240 ppm and 480 ppm jackfruit-
derived fraction respectively. The profile of the composition of the prepared diets are 
listed in Table 1. At day 56 after the day when AOM was injected, the mice were 
sacrificed to collect colon tissue and plasma for analysis. For tumor analysis, colon 
tissues were cut open longitudinally and then washed with PBS. The washed tissues were 
inspected under a dissection microscope for quantification of colon tumor. The tumor 
size was calculated with the followed formula: tumor size =  𝜋 ∗ (𝑑/2)2 (d is the 
diameter of each tumor).  
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Table 1. Animal diet Composition 
Table 1. Animal diet Composition 






Casein  200 200 200 
Cellulose 50 50 50 
Choline Bitartrate  2.5 2.5 2.5 
Cornstarch  367.5 367.5 367.5 
Dyetrose 132 132 132 
L-Cysine 3 3 3 
Mineral Mix 
#210025 
35 35 35 
Sucrose 100 100 100 
Vitamin Mix 
#310025  
10 10 10 
Commercial corn 
oil 
100 100 100 
PEG 400 (mL/kg) 5 5 5 
Jackfruit-derived 
fraction 
0 0.24 0.48 
 
2.2.2 RT-PCR analysis of gene expression in colon tissues  
For the analysis of gene expression, colon tissues from the same locations were 
frozen by liquid nitrogen and then got grounded. TRIzol reagent (Invitrogen, Carlsbad, 
CA) was added into the grounded samples to isolate total RNA from the colon tissues. 
The quality of the extracted RNA was measured with a NanoDrop Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA) and the RNA was reverse transcript into 
cDNA with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 
Foster City, CA) following the manufacturer’s instructions. A DNA Engine Opticon 
system (Bio-Rad Laboratories, Hercules, CA) with Maxima SYBR-green Master Mix 
(Thermo Fisher Scientific) was used for the performance of RT-PCR. The sequences of 
mouse-specific primers (Thermo Fisher Scientific) used were listed as in Table 2. The 
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results of target genes were normalized to glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) and expressed to the mice treated with control diets using the 2-ΔΔCt method.  
Table 2. Sequences of primers used in RT-PCR 
Table 2. Sequences of primers used in RT-PCR  
Gene  Forward primer  Reverse primer  
Gapdh  AGGTCGGTGTGAACGGATTTG  TGTAGACCATGTAGTTGAGGTCA  
Il-6  TAGTCCTTCCTACCCCATTTCC  TTGGTCCTTAGCCACTCCTTC  
Ifn-γ  ATGAACGCTACACACTGCATC  CCATCCTTTTGCCAGTTCCTC  
Axin2  TGACTCTCCTTCCAGATCCCA  YGCCCACACTAGGCTGACA  
Vegf  GCACATAGAGAGAATGAGCTTCC  CTCCGCTCTGAACAAGGCT  
Myc  ATGCCCCTCAACGTGAACTTC  GTCGCAGATGAAATAGGGCTG  
Pena TTTGAGGCACGCCTGATCC GGAGACGTGAGACGAGTCCAT 
 
2.2.3 Histological analysis of colon tissues  
Parts of the dissected colon tissues were fixed in 4 % formalin (Thermo Fisher 
Scientific) for 48 hours. For H&E staining, the fixed tissues were embedded in paraffin 
(Thermo Fisher Scientific) and sliced by Rotary Microtome (Thermo Fisher Scientific) to 
5 μm sections, and then dewaxed in serial xylene (Thermo Fisher Scientific) and 
rehydrated through graded ethanol solutions (Phamoc-Aaper, Brookfield, CT), stained 
with hematoxylin and eosin (Sigma-Aldrich, St. Louis, MO), examined with a light 
microscopy. To conduct immunohistochemistry analysis, the sections were heated in 0.01 
M citrate buffer (pH 6.0) to 95 °C for 10 minutes to perform the antigen retrieval in a PT 
Module antigen retrieval device (Thermo Fisher Scientific). The samples were incubated 
with primary antibodies against PCNA and β-catenin (Cell Signaling Technology) at 4 °C 
overnight. The sections were applied with Horseradish peroxidase (HRP)-conjugated 
secondary antibodies, and then stained with chromogen 4-diaminobenzidine according to 
the instruction of HRP/DAB (ABC) Detection IHC kit (Abcam). The samples were then 
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counterstained for one minute with hematoxylin. Light microscope was latter used for 
observation of the positive expression of PCNA and β-catenin, and the quantification of 
the expression was done with ImageJ software.  
2.2.4 Statistical analysis  
All data were expressed as the mean ± standard error of the mean (SEM). Statistical 
significance was determined by the Mann-Whitney test for the comparison between the 
vehicle and jackfruit-derived fraction treatment groups. The statistical analysis was 
performed with Prism 7.0 Version (Graphpad Software Inc., USA), and a P value less 
than 0.05 was used as the level suggesting statistical significance.  
2.3 Results  
2.3.1 Effect of jackfruit-derived fraction on body weight of mice 
All groups of mice were injected with 1mg/ml AOM (dissolved in PBS) at week 0 
and then stimulated with drinking water containing 2% DSS for seven days, in order to 
induce colon cancer, after two weeks’ pre-treatment (see scheme of animal experiment in 
Figure 1). Body weight of mice were recorded every 7 days through the whole treatment 
process (Figure 2). New diets were given to all groups of mice after seven days of DSS 
treatment. Specifically, diets for all three groups consisted of 10 wt/wt % commercial 
corn oil and 0.5 mL/g % PEG 400 while the diet for low dose and high dose jackfruit-
derived fraction groups also consisted of 240 ppm and 480 ppm jackfruit-derived fraction 
respectively. After the week treated with DSS in water, the vehicle group mice showed 
more stability in weight change than the mice treated with 480 ppm jackfruit-derived 
fraction diet and the mice treated with 240 ppm jackfruit-derived fraction group mice. 
Later during the treatment process, the mice treated with 240 ppm jackfruit-derived 
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fraction diet showed a tendency to gain more weight than the mice treated with vehicle 
diet and 480 ppm jackfruit-derived fraction diet, although the increase was not 
significant.  
 
Figure 1: Animal experiment studying the effects of jackfruit-derived fraction (240 ppm, 480 ppm) on the AOM/DSS-
induced colon tumor.t 
 
Figure 2: Effect of jackfruit-derived fraction (240 ppm, 480 ppm) on the body weight of mice. 
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2.3.2 Jackfruit-derived fraction mitigates AOM/DSS-induced colon tumorigenesis in 
vivo  
As shown by the data, the mice treated with 480 ppm jackfruit-derived fraction 
showed no significant change in total tumor size of the mice for vehicle group vs 480 
ppm jackfruit-derived fraction group (Figure 3B,  33.77 ± 0.84 for vehicle group vs 2.35 
± 0.71 for 480 ppm jackfruit-derived fraction group, P = 0.1188, mean ± SEM), while 
there are a significant decrease in tumor numbers of each mouse for vehicle group vs 480 
ppm jackfruit-derived fraction group, up to 46% decrease compared with the mice treated 
with only vehicle (Figure 3A, 3.9 ± 0.67 for vehicle group vs 2.1 ± 0.31 for 480 ppm 
jackfruit-derived fraction group, P = 0.0431, mean ± SEM), indicating alleviated colon 
tumorigenesis. Considering the lack of clear differences between vehicle group and 240 
ppm jackfruit-derived fraction group in tumor numbers and in total tumor size of each 
mouse (Figure 3A-B), all following experiments are not conducted on 240 ppm jackfruit-




Figure 3: Compared with mice treated with only vehicle and 240 ppm jackfruit-derived fraction, AOM/DSS-induced 




Consistent with the decreased tumorigenesis in colon, the pro-inflammatory cytokines 
(Il-6 and Inf-γ) (Figure 4 A-B) and some pro-tumorigenic genes (Axin2, Vegf, Myc and 
Pcna) (Figure 5 A-D) were less expressed in the mice treated with 480 ppm jackfruit-
derived fraction than the mice in vehicle group. H&E staining showed a decreased size of 
tumor in the colon of mice treated with 480 ppm jackfruit-derived fraction (Figure 6 A). 
Immunohistochemistry validated that 480 ppm jackfruit-derived fraction decreased the 











Figure 5: 480 ppm jackfruit-derived fraction consumption decreases the 
expression of pro-tumorigenic genes in vivo.  
Figure 5: 480 ppm jackfruit-derived fraction consumption decreases the expression of pro-tumorigenic genes in vivo. 
Expression of pro-tumorigenic genes, including (A) Axin2, (B) Vegf, (C) Myc, 
(D)Pcna, in colon tissues. The data are expressed by mean ± SEM, and statistical 




Figure 6: Immunohistochemical staining of H&E and PCNA. 
Figure 6: Immunohistochemical staining of H&E and PCNA.  
The data are expressed by mean ± SEM, and statistical significance is determined by 




As the third most common cancer and the fourth most common cause of cancer-
related death, with 700,000 deaths per year, exceeded only by lung, liver and stomach 
cancers, the incidence of colorectal cancer is increasing year by year, with 200,000 new 
cases per year from 1990 to 2012, calling more studies to be conducted on colorectal 
cancer prevention. Many studies have shown the potential of jackfruit, a common tropical 
fruit that is rich in carbohydrates, proteins, vitamins, minerals, and phytochemicals, in 
protecting against colon tumorigenesis in vitro. Our collaborators provided us the 
jackfruit-derived extract. Here, we conducted an AOM/DSS mice study on the potential 
chemopreventative effect of jackfruit-derived extracts on colon tumorigenesis.  
We have found that the dietary consumption of 480 ppm jackfruit-derived extracts 
could mitigate the development of colon tumorigenesis in C57BL/6 male mice. We 
started the experiments with three groups: 240 ppm jackfruit-derived extracts, 480 ppm 
jackfruit-derived extracts and vehicle. However, no significant difference of the 
quantification of colon tumorigenesis was observed between 240 ppm jackfruit-derived 
extracts group and vehicle group. Therefore, further experiments were not conduced on 







Our experiments studied the effect of jackfruit-derived extracts on the development of 
colon tumorigenesis in C57BL/6 male mice. The analysis results all together supported 
that dietary consumption of high dose (480 ppm) jackfruit-derived extracts could 
alleviate colorectal tumorigenesis in mice. However, there are still some limits in the in 
vivo experiment. Therefore, much further work could be done in the future to investigate 
more in detail on the effect of this extract on colon tumorigenesis. 
3.1 Dosage study  
The quantification of colon tumorigenesis has shown that 240 ppm jackfruit-derived 
extract has no significant effect on alleviating colitis associated tumorigenesis in 
C57BL/6 male mice, possibly due to the lack of strong potency of natural products on the 
protection against carcinogenesis, when compared to synthetic cancer drugs. The fact that 
240 ppm jackfruit-derived extract did not show significant effect suggests the effect 
might be dose-dependent. Thus, we can later set up more groups of different dosage to 
investigate the dose effect on the model.  
3.2 Model study  
Our experiment was done in only C57BL/6 male mice model. Such mice need an 
AOM/DSS treatment to initiate colitis-associated colorectal cancer. Considering the 
different causes of colorectal cancer among humans, other mouse models including 
genetically engineered mice could be used to investigate the effect of jackfruit on 
hereditary colorectal cancer including FAP and HNPCC for future studies. 
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3.3 Gender and age  
We conducted the experiments only on male mice aged 7 weeks. However, it is 
reported that sex is also a factor in the risk of developing colorectal cancer, with 9.2% in 
women and 10% in men 
By gender, CRC is the second most common cancer in women (9.2%) and the third in 
men (10%). A study conducted in 2008 has suggested that the main risk factor for 
colorectal cancer is age: past the fifth decade of life, the risk of developing CRC is 
markedly increased, while the onset of colorectal cancer below the age of fifty is rare 
(apart from inherited cancers) [89]. Both findings indicate the need for conducting in vivo 
experiments on the effect of jackfruit on colorectal cancer among different sex and age 
groups. 
3.4 Composition study 
The jackfruit-derived extract used in this experiment is believed to a crude extract 
containing many different compounds. It is difficult to understand that which one or 
which ones of the extract is playing a role on the development of colorectal cancer in the 
mice, calling for the need of isolating each compound, and assessing the potential of each 
compound on the effect of colorectal carcinogenesis. Moreover, we are unsure if any 
compositions of the extract mixture have changed from the time of diet preparation until 
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